Home › Funds › ADAR1 Capital Management, LLC › CTMX

ADAR1 Capital Management, LLC position in CTMX

CYTOMX THERAPEUTICS INC. · Health Care

ADAR1 Capital Management, LLC reported holding 3,365,118 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q2 2026 13F filing — a position valued at US$12.6M, representing 0.70% of its reported portfolio and ranking #40 among its reported holdings. ADAR1 Capital Management, LLC has disclosed CTMX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)3.37M sh
Reported value held$12.62M
Portfolio Weight0.70%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's CTMX position evolved

ADAR1 Capital Management, LLC first disclosed a stake in CTMX in Q1 2024 at 155,000 shares (US$338K). The position peaked in Q1 2026 at 3,410,190 shares, worth US$16.0M. Across 10 filings, ADAR1 Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,365,118 shares valued at US$12.6M — a reduction of -45,072 shares quarter over quarter.. Notable position changes include a 269% increase in Q2 2024 (shares fell 3% over the following quarter), a 6451% increase in Q2 2025 (shares rose 41% over the following quarter), a 3310% increase in Q1 2026 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 155.00K $337.90K New
Q2 2024 572.17K $698.05K Add
Q3 2024 903.96K $1.07M Add
Q4 2024 145.04K $149.39K Reduce
Q1 2025 47.04K $29.91K Reduce
Q2 2025 3.08M $6.99M Add
Q3 2025 4.05M $12.90M Add
Q4 2025 100.00K $426.00K Reduce
Q1 2026 3.41M $16.03M Add
Q2 2026 3.37M $12.62M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CTMX and 13F data

CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 45 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CTMX

All CTMX fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held CTMX?

ADAR1 Capital Management, LLC has disclosed CTMX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is ADAR1 Capital Management, LLC's current position in CTMX?

As of Q2 2026, ADAR1 Capital Management, LLC holds 3.37M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $12.62M, representing 0.70% of its reported portfolio and ranking #40.

Has ADAR1 Capital Management, LLC been buying or selling CTMX?

In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in CTMX. The position peaked in Q1 2026 at 3.41M shares.

Which other funds hold CTMX?

Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.